Emmanuel Antonarakis

About

Dr. Takako Araki is an Associate Professor in the Division of Endocrinology, Diabetes and Metabolism at the University of Minnesota. Her research is dedicated to the quality improvement of pituitary perioperative patient care and the study of various pituitary disorders. She leads the Araki Lab, which focuses on understanding pituitary development and disorders, utilizing human iPS cells in their analysis. The lab investigates post-COVID pituitary dysfunction and aims to advance knowledge in pituitary-related health issues. The lab includes members such as Ryan Lawrence, a chemical engineering student; Mayu Tsuzuki, a study coordinator and lab manager; Gwyn Schmidt, an undergraduate student in Genetics, Cell Biology, and Development; Steven Sims, who investigates post-COVID pituitary dysfunction; Matthew Walters, a biochemistry graduate; and Joel Pardo, a medical scientist trainee with interests in research and gardening. The lab also collaborates with international researchers, including Dr. Ryusaku Matsumoto from Kyoto University, whose research involves in vitro analysis of pituitary development using human iPS cells.

Research topics

• Internal medicine
• Medicine
• Oncology
• Cancer research
• Urology
• Chemistry
• Biology
• Biochemistry
• Gynecology
• Surgery

Selected publications

• A clinical-genetic (CG) circulating tumor DNA (ctDNA)-based prognostic model for predicting overall survival (OS) in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with potent androgen receptor inhibition (Alliance).

  Journal of Clinical Oncology · 2024 · 2 citations

  5007 Background: We have previously developed and validated a clinical prognostic model of OS in mCRPC men that included these variables: performance status, disease site, opioid analgesic use, lactate dehydrogenase, albumin, hemoglobin, prostate specific antigen, and alkaline phosphatase. The goal of this analysis is to improve upon the clinical model of OS by incorporating ctDNA pathogenic genetic alterations (PGAs). Methods: Data from the A031201 phase 3 trial of enzalutamide+/- abiraterone w…

  PublisherDOI

• HLA Class I Expression is Associated with Increased Immune Cell Density and PTEN Loss in Prostate Cancer

  Molecular Cancer Research · 2026-05-01

  article

  Human leukocyte antigen Class I (HLA-I) downregulation in prostate cancer may contribute to tumor immune evasion. We digitally quantified HLA-I protein expression in a cohort of racially diverse and molecularly characterized prostatectomy specimens, as well as additional cohorts of metastatic hormone-sensitive (mHSPC) and castration-resistant prostate cancer (mCRPC). We confirm that HLA-I protein expression is negatively associated with intragenic methylation of major HLA-I genes, downregulated…

  PublisherDOI

• B7-H3 Gene Expression Shapes Prognosis and Therapeutic Opportunities Across Prostate Cancer Patient Groups

  Clinical Cancer Research · 2026-04-21

  article

  PURPOSE: B7-H3 (CD276) represents a promising therapeutic target tested in high-risk localized and treatment-refractory metastatic prostate cancer (PC). To guide therapeutic development and treatment strategies, we examined prostate tumors and evaluated expression, molecular features, and overall survival (OS), accounting for tissue site, hormone-sensitivity status, and race. EXPERIMENTAL DESIGN: 8,157 PC samples with paired DNA/RNA were analyzed based on annotations by tissue site, self-reporte…

  PublisherDOI

• Rethinking the role of synergy calculations in the next century of drug combination discovery

  Med · 2026-05-01

  article
  PublisherDOI

• Supplementary Table 2 from Metastatic Prostate Cancers with <i>BRCA2</i> versus <i>ATM</i> Mutations Exhibit Divergent Molecular Features and Clinical Outcomes

  2025-11-25

  articleOpen accessSenior author

  <p>Comparison of the frequencies of additional molecular features between non-castrate (NC) and castrate (C) samples in ATMm, BRCA2m, HRDother, and HRP groups. The significant differences between the two groups are highlighted (red box).</p>

  PublisherDOI

Recent grants

• The aberrant androgen receptor underlies abiraterone/enzalutamide resistance

  NIH · $1.5M · 2015–2020

Frequent coauthors

• Mario A. Eisenberger

  673 shared

• Michael A. Carducci

  627 shared

• Samuel R. Denmeade

  502 shared

• Channing J. Paller

  Sidney Kimmel Comprehensive Cancer Center

  484 shared

• Jun Luo

  Johns Hopkins University

  443 shared

• Hao Wang

  402 shared

• Kenneth J. Pienta

  326 shared

• Changxue Lu

  Johns Hopkins Medicine

  304 shared

Labs

• Araki LabPI

Similar researchers at University of Minnesota

• Elizabeth Seaquisth-53
• Mahsa Abassih-34
• Stuart Amateauh-32